What makes the difference
To prevent this, practice proper site rotation keep at least a 1-inch gap between injection sites and avoid reusing the exact location for at least 4 weeks
Of these, 31 were approved large-volume SC agents and 83 were clinical-stage candidates, demonstrating the potential for significant growth in this area.2 Another 68 IV formulations were identified by the study authors as potential candidates for transition from an IV to an SC route
Always Rigorously Third-Party Tested Every product page includes independent lab test results for every peptide we sell
GLP-1s, while highly effective, are therefore only one piece of a multidisciplinary health care puzzle
In return for the license, Ascendis will be eligible to receive total payments of up to $285 million in upfront, development, and regulatory milestone payments for the lead program